Hematology Unit, 3rd University Clinic of Internal Medicine, Sotiria General Hospital, Athens Medical School, Athens, Greece.
J BUON. 2021 Mar-Apr;26(2):569-579.
To investigate a possible chemorefractoriness mechanism of a Diffuse Large B-Cell Lymphoma (DLBCL) histological subtype, specifically of DLBCL, not otherwise specified (DLBCL, NOS), namely the effect of programmed cell death-1 (PD-1) immunoreceptor signalling, considering that the identification of additional negative prognostic factors can lead to better prognostication and therapeutic approaches.
We conducted a retrospective study of DLBCL, NOS patients, gathering their clinical features and combining them with PD-1 and its ligand (PD-L1) expression at the time of diagnosis as well as their response to treatment.
No statistically significant difference was found when comparing PD-L1 positive to PD-L1 negative patients, while overall survival (OS) and duration of complete response (CR) were better for PD-L1 negative patients but the difference was not statistically significant.
PD-L1 expression was not found to have any prognostic value for our cohort of DLBCL, NOS patients. What is more, the number of PD-1 positive tumour infiltrating lymphocytes was not associated with PD-L1 expression neither on malignant nor on non-malignant cells.
研究弥漫性大 B 细胞淋巴瘤（DLBCL）组织学亚型（尤其是未特指弥漫性大 B 细胞淋巴瘤，DLBCL，NOS）发生化学抵抗的可能机制，即程序性细胞死亡受体 1（PD-1）免疫受体信号的作用。考虑到确定更多的负性预后因素可能导致更好的预后和治疗方法。
我们对 DLBCL，NOS 患者进行了回顾性研究，收集了他们的临床特征，并将其与诊断时的 PD-1 及其配体（PD-L1）表达以及对治疗的反应相结合。
PD-L1 阳性与 PD-L1 阴性患者之间无统计学差异，PD-L1 阴性患者的总生存期（OS）和完全缓解（CR）持续时间更好，但差异无统计学意义。
PD-L1 表达对我们的 DLBCL，NOS 患者队列没有任何预后价值。此外，PD-1 阳性肿瘤浸润淋巴细胞的数量与恶性细胞和非恶性细胞上的 PD-L1 表达均无相关性。
